| |
| |
|
| Insider
Information: |
Thorp Clay |
| Relationship: |
Director |
| City: |
Durham |
| State: |
NC |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
80,215 |
|
|
Indirect Shares
|
8,859,224 |
|
|
| Direct
Value |
$54,705 |
|
|
|
Indirect Value
|
$5,847,112 |
|
|
| Total
Shares |
8,939,439 |
|
|
| Total
Value |
$5,901,816 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 20.3%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Clearside Biomedical, Inc. |
CLSD |
Director |
2023-09-25 |
40,522 |
2023-09-25 |
3,545,040 |
Premium* |
|
|
G1 Therapeutics Inc |
GTHX |
10% Owner |
|
0 |
2017-05-16 |
213,114 |
Premium* |
|
|
Phasebio Pharmaceuticals Inc |
PHAS |
Director |
2023-05-19 |
36,693 |
2023-05-19 |
3,545,040 |
Premium* |
|
|
Vigil Neuroscience, Inc. |
VIGL |
Director |
2022-05-17 |
3,000 |
2022-05-17 |
1,556,030 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CLSD |
Clearside Biomedical, Inc... |
Director |
– • – |
2023-09-25 |
4 |
B |
$0.86 |
$8,600 |
D/D |
10,000 |
40,522 |
2.39 |
% |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Director |
– • – |
2023-05-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
36,693 |
0 |
- |
|
| CLSD |
Clearside Biomedical, Inc... |
Director |
– • – |
2022-12-21 |
4 |
B |
$1.02 |
$14,266 |
D/D |
14,000 |
30,522 |
2.39 |
% |
|
| CLSD |
Clearside Biomedical, Inc... |
Director |
– • – |
2022-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,522 |
16,522 |
0 |
- |
|
| CLSD |
Clearside Biomedical, Inc... |
Director |
– • – |
2022-12-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,406,507) |
3,545,040 |
0 |
- |
|
| VIGL |
Vigil Neuroscience, Inc. |
Director |
– • – |
2022-05-17 |
4 |
B |
$2.97 |
$44,189 |
I/I |
14,893 |
1,556,030 |
2.1 |
- |
|
| VIGL |
Vigil Neuroscience, Inc. |
Director |
– • – |
2022-05-16 |
4 |
B |
$2.76 |
$60,221 |
I/I |
21,802 |
1,541,137 |
2.1 |
- |
|
| VIGL |
Vigil Neuroscience, Inc. |
Director |
– • – |
2022-03-28 |
4 |
B |
$7.20 |
$21,604 |
D/D |
3,000 |
3,000 |
2.39 |
- |
|
| VIGL |
Vigil Neuroscience, Inc. |
Director |
– • – |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
1,254,335 |
1,254,335 |
0 |
- |
|
| VIGL |
Vigil Neuroscience, Inc. |
Director |
– • – |
2022-01-11 |
4 |
B |
$14.00 |
$3,710,000 |
I/I |
265,000 |
1,519,335 |
2.1 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Director |
– • – |
2021-08-18 |
4 |
B |
$3.00 |
$30,000 |
D/D |
10,000 |
32,943 |
2.39 |
- |
|
| CLSD |
Clearside Biomedical, Inc... |
Director |
– • – |
2021-02-10 |
4/A |
AS |
$4.43 |
$145,627 |
D/D |
(32,873) |
4,951,547 |
0 |
- |
|
| CLSD |
Clearside Biomedical, Inc... |
Director |
– • – |
2021-02-10 |
4 |
AS |
$4.43 |
$145,627 |
I/I |
(32,873) |
3,433,521 |
0 |
% |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Director |
– • – |
2020-11-24 |
4 |
B |
$3.50 |
$7,000 |
D/D |
2,000 |
22,943 |
2.39 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Director |
– • – |
2020-11-23 |
4 |
B |
$3.67 |
$11,010 |
D/D |
3,000 |
20,943 |
2.39 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Director |
– • – |
2020-11-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(52,397) |
0 |
0 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Director |
– • – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,144 |
17,943 |
0 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Director |
– • – |
2020-11-16 |
4 |
A |
$0.00 |
$0 |
I/I |
10,586 |
15,432 |
0 |
- |
|
| CLSD |
Clearside Biomedical, Inc... |
Director |
– • • |
2019-11-22 |
4 |
A |
$1.05 |
$1,599,999 |
I/I |
1,518,026 |
4,984,420 |
0 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Director |
– • • |
2019-07-01 |
4 |
AS |
$14.00 |
$40,712 |
I/I |
(2,908) |
415,959 |
0 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Director |
– • • |
2019-06-18 |
4 |
AS |
$14.00 |
$5,600 |
I/I |
(400) |
416,418 |
0 |
- |
|
| CLSD |
Clearside Biomedical, Inc... |
Director |
– • • |
2018-12-06 |
4 |
B |
$1.36 |
$10,880 |
D/D |
8,000 |
8,000 |
3.92 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Director |
– • • |
2018-12-04 |
4 |
B |
$3.13 |
$12,520 |
D/D |
4,000 |
15,799 |
3.92 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Director |
– • • |
2018-10-22 |
4 |
B |
$5.00 |
$1,500,000 |
I/I |
300,000 |
416,481 |
2.25 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Director |
– • • |
2018-10-22 |
4 |
A |
$0.00 |
$0 |
I/I |
2,158,049 |
266,481 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
